



NGL Fine-Chem Limited

Regd. Office : 301, E - Square, Subhash Road, Vile Parle East, Mumbai 400057, Maharashtra, INDIA
Tel.: (+91 22) 26636450 Fax : 26108030 Email : info@nglfinechem.com CIN : L24110MH1981PLC025884, Website : www.nglfinechem.com

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Date: 8th February, 2019

Subject: Outcome of the Board Meeting Dated 8th February, 2019.

Dear Sir,

This is to inform you that the Fourth Meeting of the Board of Directors of NGL Fine-Chem Limited for the financial year 2018-2019 held at the registered office of the Company on Friday, the February 8, 2019 at 3.30 p.m and concluded at 6.00 p.m approved the following:

1. Approved Standalone Unaudited Financial Results for the quarter ended 31st December, 2018 pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations.
2. Approved re-appointment of Mr. Milind Shinde, Independent Director of the Company for a further term of 5 [Five] years, w.e.f 1st April, 2019 subject to the approval of shareholders in the ensuing Annual General Meeting.
3. To take on record the resignation of Ms. Esha Kulkarni, Company Secretary and Compliance Officer, of the Company w.e.f 8th February, 2019.
4. To take on record the appointment of Mrs. Pallavi Pednekar [ACS 33498] as the Company Secretary and Compliance Officer w.e.f 9th February, 2019.

Kindly take the same on your record and acknowledge receipt of the same.

Thanking You,

Yours truly,

For NGL Fine-Chem Ltd

Rahul Nachane
Managing Director
DIN: 00223346



MANEK & ASSOCIATES

CHARTERED ACCOUNTANTS

3, Shanti Kunj, 17, Prarthana Samaj Road, Vile Parle (East), Mumbai - 400 057.

Off. # 2618 5110
2618 5137
Fax # 2618 4912
shallesh.manek@gmail.com
www.camanek.com

SHAILESH MANEK

B.Com.(Hons), Grad. C.W.A., F.C.A.

LIMITED REVIEW REPORT OF THE AUDITORS

Review Report to,
The Board of Directors,
NGL Fine-Chem Limited

We have reviewed the accompanying statement of Unaudited Financial Results ('the Statement') of NGL Fine-Chem Limited ("the Company") for the quarter ended DECEMBER 31, 2018., prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initiated by us for the purpose of identification.

This statement is the responsibility of the Company's Management and has been reviewed by the Audit Committee, at its meeting held on February 08th, 2019, and , approved by the Board of Directors, at its meeting held on February 08th, 2019. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards, i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014- and other recognised accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.



For MANEK & ASSOCIATES
Chartered Accountants
Firm's Registration No.:126679W

Shallesh Manek
(SHAILESH MANEK)

Proprietor

Membership Numbe:.034925

MUMBAI

DATED: 08/02/2019.

NGL FINE-CHEM LIMITED

Regd Office: 301, Esquare, Subhash Road

Vile Parle (East), Mumbai 400 057

CIN: L24110MH1981PLC025884



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER 2018

PART I

Rupees in lakhs

		Quarter ended			Nine month ended		Year Ended
		31.12.2018 (Unaudited)	30.09.2018 (Unaudited)	31.12.2017 (Unaudited)	31.12.2018 (Unaudited)	31.12.2017 (Unaudited)	31.03.2018 (Audited)
I	Revenue from Operations	3,447.31	3,892.04	2,928.70	10,825.35	7,943.57	11,567.81
II	Other Income	73.40	184.37	160.21	368.15	382.57	257.15
III	Total Revenue (I+II)	3,520.71	4,076.41	3,088.91	11,193.50	8,326.14	11,824.96
IV	Expences :						
	a) Cost of Material Consumed	1,721.59	1,555.73	1,355.81	4,899.88	3,454.20	5,038.07
	b) (Increase)/Decrease in stock in trade and work in progress	(393.37)	139.90	(153.88)	(404.95)	(174.70)	(451.38)
	c) Excise Duty paid						201.93
	d) Employee benefits expenses	507.10	566.88	465.90	1,555.37	1,332.95	1,837.17
	e) Finance Costs	64.21	52.39	58.62	175.25	88.90	155.50
	f) Depreciation and amortisation expenses	162.42	149.43	60.95	468.88	307.89	456.07
	g) Other expenses	874.49	940.30	723.66	2,721.18	1,986.57	2,807.32
	Total Expenses (IV)	2,936.44	3,404.63	2,511.06	9,415.61	6,995.81	10,044.68
V	Profit/(loss) before exceptional items and tax (III-IV)	584.27	671.78	577.85	1,777.89	1,330.33	1,780.28
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	584.27	671.78	577.85	1,777.89	1,330.33	1,780.28
VIII	Tax Expense						
	a) Current Tax	(130.00)	(220.00)	(73.00)	(530.00)	(222.00)	(381.00)
	b) MAT Tax						57.00
	b) Prior Years	-	-	-	0.00	4.88	5.08
	c) Deferred Tax	(47.12)	(9.91)	(85.36)	83.60	(162.88)	(202.06)
IX	Profit/ (Loss) for the period from continuing operations (VII-VIII)	407.15	441.87	419.49	1,331.49	950.33	1,259.30
X	Other Comprehensive Income						
	a. Gain/(Loss) on actuarial valuation of post employment benefits	(24.31)	(4.50)	6.68	(5.69)	5.72	5.40
	b. Deferred tax on above	7.08	1.31	(1.72)	1.66	(2.63)	(1.50)
	c. Other Comprehensive Income (Net of Tax)	(17.23)	(3.19)	4.96	(4.03)	3.09	3.90
XI	Total Comprehensive Income	389.92	438.68	424.45	1,327.46	953.42	1,263.20
XII	Paid-up Equity Share Capital (Face Value of the Share Rs. 5/- each)	308.90	308.90	308.90	308.90	308.90	308.90
XXIII	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year	N.A	N.A	N.A.	N.A	N.A	6,895.28
XIV	Earnings Per Share (EPS)						
	a) Basic (Rs.)	6.59	7.15	6.87	21.55	15.43	20.38
	b) Diluted (Rs.)	6.59	7.15	6.87	21.55	15.43	20.38

Notes:

- 1 The above results were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on Friday, 8th February, 2019. These results are subject to Limited Review by the Statutory Auditors of the Company.
- 2 The Company is of the view that it manufactures pharmaceuticals, which is a single business segment in accordance with IND-AS 108 "Operating Segment" notified pursuant to Companies (Indian Accounting Standards) Rule 2015.
- 3 Previous year figures have been regrouped or reclassified wherever necessary

Place Mumbai
Date 8th February 2019

For and On behalf of Board of Directors,

Rahul Nachane
Rahul Nachane
Managing Director

